3 Biotechs Expecting Data

The release of clinical trial data can be make-or-break moments for biotech companies. Three companies, Exelixis (NASDAQ: EXEL  ) , Vertex Pharmaceuticals (NASDAQ: VRTX  ) , and Prana Biotechnology (NASDAQ: PRAN  ) are finishing up trials, and should release data shortly.

Exelixis' trials, dubbed Comet 1 and Comet 2, will measure Cometriq's ability to increase survival and decrease pain associated with bone metastasis in patients with prostate cancer. Cometriq is already approved to treat thyroid cancer, but the prostate cancer data, which will read out later this year, could increase the drug's market substantially.

Vertex is also testing a drug that's already been approved, Kalydeco, but the biotech is combining Kalydeco with another drug from its pipeline, VX-809, in patients with cystic fibrosis. If the two trials -- Traffic and Transport -- are positive, Vertex will be able to treat a larger portion of cystic fibrosis patients than those who respond to Kalydeco alone.

Finally, Prana Biotechnology has said it will release data for its drug PBT2 in patients with Alzheimer's disease this month.

Watch the video below for a full take on the trials and predictions from Fool contributor Brian Orelli and health-care bureau chief Max Macaluso.

Finding companies before they're hot
The key to investing in hyper-growth markets is to find a small-cap "pure-play," and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 23, 2014, at 6:44 AM, cmarystewart wrote:

    Seriously? Your comments on Prana? The HD analysis was pre-specified. They didn't do thousand of tests looking for a movement as you claim. And the cognitive end point that improved also improved in a previous trial - that was why it was such a big deal! You guys need to do some quality control on your own work. At least this commentary was better than the article authored by Leo Sun (which I note you took down). Referring to ex-ante cohort characteristics (which are designed to be as similar as possible for scientific reasons) and claiming that showed the drug had no impact (when in fact there was no reference to ex-post results in the chart because it showed the groups' characteristics prior to dosing) was a real doozy! You owed Prana an apology on that one.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2885506, ~/Articles/ArticleHandler.aspx, 12/18/2014 3:27:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement